The Apple Watch’s atrial fibrillation (AFib) detection has undoubtedly resonated in the wearables market, even though it is now at the center of a patent lawsuit,media reported. Apple is naturally proud that this feature can save lives. While other smart wearable device makers are struggling to catch up and catch up with it, Withings appears to be one of the first companies to do so, with the launch of the new ScanWatch hybrid smartwatch.
Not only does the watch feature AFib detect, it also brings another health feature to the wearer’s wrist.
Many people might compare it to the Apple Watch. Both use photoelectric volume stroke (PPG) to continuously monitor the wearer’s heart rate and, when needed, provide a fast 30-second electrocardiogram to confirm the irregular heart rate. All the wearer needs to do is touch the watch’s border while reading the etogram and then provide the accumulated data to a professional for diagnosis.
AFib is considered one of the most difficult to detect because it has no obvious symptoms. Another such disease is sleep apnea, which withings proudly announces that the new watch has the ability to detect the disease’s presence. But the test is indirect and uses SpO2 sensors to measure oxygen saturation levels during sleep, which may be related to apnea and other apnea.
Considering that the Apple Watch, which has only AFib detection, has made a big achievement, the increase in sleep apnea detection may give the Withings ScanWatch an advantage over other smartwatches. But professionals also advise users to seek medical advice instead of jumping to conclusions, after all, these features are used only to detect symptoms and not to make a diagnosis.
But as with the Apple Watch, the biggest obstacle facing Withings is how to get approval from the regulatory board. By the end of 2020, the Withings ScanWatch will sell for $249 (38mm) and $299 (42mm) respectively.